MedTrace Logo

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma

NCT03506139 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-09-09

No results posted yet for this study

Summary

This clinical trial increases radiation to areas of the brain considered to be at risk for cancer. The at-risk areas are identified by a biological MRI scan. The study will look at side effects of the radiation and overall survival.

Conditions

Interventions

RADIATION

External beam radiation therapy

Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions

Sponsors & Collaborators

  • Holden Comprehensive Cancer Center

    collaborator OTHER

  • John M. Buatti

    lead OTHER

Principal Investigators

  • John M. Buatti, MD · University of Iowa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2024-12-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506139 on ClinicalTrials.gov